During cancer progression, the phosphorylation of CCDC106 by the protein kinase CK2 is essential for p53 degradation, and a CK2 inhibitor can block the translocation of CCDC106 into the nuclei of mutant p53 cells3. This evidence concerns the gene TP53 and cancer.